Religare Enterprises Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 7 Aug 2026 | Finance | Market Cap: ₹8.6K Cr
Religare aims for meaningful long-term growth across its businesses, backed by recent capital infusion and strategic focus on scaling subsidiaries (Page 25). Religare Enterprises and subsidiaries are positioned for long-term growth with significant capital infusion (INR750 crores preferential issue by Burman family) aimed at scaling multiple financial services platforms, including Care Health Insurance, broking, and housing finance.
From Religare Enterprises Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹232
Market Cap
₹8.6K Cr
P/E Ratio
99.6
How does Religare Enterprises Ltd rank in Finance?
Compare Religare Enterprises Ltd against every Finance company this quarter on revenue, margins and earnings-call signals.
Religare Enterprises Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.5K Cr, net profit ₹96 Cr.
Full financials →📊 Revenue & Sales Performance
- →Religare aims for meaningful long-term growth across its businesses, backed by recent capital infusion and strategic focus on scaling subsidiaries (Page 25).
- →Care Health Insurance business is growing rapidly, already creating shareholder value, with plans to scale further (Page 22).
- →Broking business targets industry-plus growth, leveraging enhanced capital and technology upgrades for faster expansion (Page 17).
- →Housing finance business plans meteoric growth in AUM over next few years, supported by strong capital and lifting of regulatory caps (Page 16).
- →Retail insurance business grew by 28%, with continued growth momentum at 22% in October, focusing on multi-channel distribution (Page 7).
- →Investment book in insurance increased by INR 900 crores post capital infusion; market share is rising steadily (Page 7).
- →Overall, focus on increasing retail market share and distribution channels including bancassurance for expanding volumes (Page 22).
📈 Profitability & Margins
- →Religare Enterprises and subsidiaries are positioned for long-term growth with significant capital infusion (INR750 crores preferential issue by Burman family) aimed at scaling multiple financial services platforms, including Care Health Insurance, broking, and housing finance.
- →Care Health Insurance targets rapid growth in retail health market share with capital to support expansion, maintain solvency, and improve profitability; combined ratio for group business is kept under 100%, ensuring sustainable underwriting.
- →Broking business expects industry-plus growth fueled by INR200 crores capital infusion, technology upgrades, and expanded product offerings.
- →Housing finance business aims for meteoric growth in AUM with recent removal of regulatory caps, INR250 crores capital infusion, and upgraded IT systems.
- →RFL is now debt-free with regulatory constraints lifted and aims for scalable, profitable growth backed by strong CRAR (~198%).
- →Overall, management targets improved profitability, efficient operations (declining Expense Over Margin), and shareholder value enhancement across subsidiaries.
🏗️ Capital Expenditure Plans
- →Capital infusion of INR 1,500 crores through preferential issue; 25% (INR 375 crores) already received and utilized.
- →INR 600 crores earmarked for Care Health Insurance for solvency, franchise expansion, and business growth.
- →INR 250 crores allocated to housing finance business to scale up operations post lifting of RBI restrictions.
- →INR 200 crores committed for broking business to enhance wealth franchise, distribution, and e-governance.
- →INR 75 crores used for loan repayment at Religare Enterprises, making it debt-free.
- →Remaining INR 375 crores planned for General Corporate Purpose (GCP), including accelerating growth in subsidiaries.
- →Ongoing IT systems upgrades across NBFC, housing finance, and broking businesses to support transformation and scalability.
- →Focus on asset-light expansion models and technology-driven growth, especially in affordable housing and digital initiatives.
💰 Fundraising & Capital Structure
- →As of now, there is no immediate requirement for further capital infusion through equity or debt for the NBFC and housing finance businesses.
- →The NBFC business has a net worth of around INR 800 crores and cash reserves of approximately INR 430 crores, making additional capital infusion unnecessary at present.
- →The housing finance business has been allocated INR 250 crores from the preferential issue for growth.
- →A total preferential issue of INR 1,500 crores was raised, with INR 375 crores earmarked for general corporate purposes, which will be used to accelerate subsidiary growth as needed.
- →Future capital infusion or fundraising plans will be evaluated based on business needs and discussed with the Board before any action.
- →Management is focused on making businesses larger and stronger before considering any further fundraising or monetization steps.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Religare Enterprises Ltd Q2 FY26 results?
Religare aims for meaningful long-term growth across its businesses, backed by recent capital infusion and strategic focus on scaling subsidiaries (Page 25). Religare Enterprises and subsidiaries are positioned for long-term growth with significant capital infusion (INR750 crores preferential issue by Burman family) aimed at scaling multiple financial services platforms, including Care Health Insurance, broking, and housing finance.
What is Religare Enterprises Ltd share price analysis?
Religare Enterprises Ltd currently shows a neutral. The stock trades at a P/E of 99.6 with a market cap of ₹8,562 Cr. Investors should review the full earnings analysis for detailed insights.
Is Religare Enterprises Ltd planning capital expenditure?
Capital infusion of INR 1,500 crores through preferential issue; 25% (INR 375 crores) already received and utilized.
Keep Religare Enterprises Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.